Translate

Friday, December 27, 2013

I'll Stick to Muggle Science, Thanks

Mr. Grant LaFleche took on naturopaths and homeopaths in his recent opinion piece in The Standard on 12/22/13.
http://www.wellandtribune.ca/2013/12/22/ill-stick-to-muggle-science-thanks

Fortunately, he has no influence and his opinions are just that. A typical skeptic always demands reproducible studies and their belief in science based medicine as the gold standard. What’s wrong with this? Answer below:

“Too many of the findings that fill the academic either are the result of shoddy experiments or poor analysis (link to article below). A rule of thumb among biotechnology venture-capitalists is that half of published research cannot be replicated. Even that may be optimistic. Last year researchers at one biotech firm, Amgen, found they could reproduce just six of 53 “landmark” studies in cancer research. Earlier, a group at Bayer, a drug company, managed to repeat just a quarter of 67 similarly important papers. A leading computer scientist frets that three-quarters of papers in his subfield are bunk. In 2000-10 roughly 80,000 patients took part in clinical trials based on research that was later retracted because of mistakes or improprieties.”

Much exciting collaborative research on the effectiveness of homeopathy is being done world-wide and now in collaboration with research institutions in the United States.

“The University of Texas MD Anderson Cancer Center in Houston – The US department of alternative medicine followed the cases presented in Corfu with lab trials using Banerji’s homeopathic medicine on cancer cells at The University of Texas MD Anderson Cancer Center (MDACC) in Houston. Dr. Sen Pathak, Prof. of Cell Biology & Genetics, at the University of Texas MD Anderson Cancer Center, Houston, collaborated in this joint research between the PBHRF and the MDACC. The research work is now complete and published. An in vitro study with the medicines has shown brilliant results in killing brain cancer cells while activating the normal cells. The paper entitled “Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer” was jointly published with Pathak S, Multani AS, of the Department of Molecular Genetics, M.D. Anderson Cancer Center, Houston, USA., in the October 2003 issue of the International Journal of Oncology. (PBHRF and the University of Texas MD Anderson Cancer Center, Houston, USA conducted jointly an in vitro research study on the effectiveness of the medicines Ruta 6 and Calcarea Phosphorica 3X in destroying brain cancer cells while activating the normal cells. The research study was published in the form of a paper in the October 2003 issue of the International Journal of Oncology.)”